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Abstract
Background: The 5-year survival rate of patients with hepatocellular cancer (HCC) was very low because of invasion and
metastasis in the early stage. Biomarkers might help predict early occurrence of invasion and metastasis. Accumulating
evidence has shown that deleted in liver cancer-1 (DLC1) may be considered as a metastasis suppressor gene in
numerous solid and hematological cancers. However, its prognostic role and mechanisms that regulate and coordinate
these activities remain poorly understood.
Methods: With the method of immunohistochemistry, the expression of DLC-1 as well as Rho A, ROCK2, moesin had
been characterized in 80 HCC tissues and adjacent noncancerous tissues. The correlation between their expression and
their relationships with clinicopathological characteristics of HCC were also investigated. In addition, the prognostic value
of DLC1 expression within the tumor tissues was assessed by Cox regression and Kaplan-Meier analysis.
Results : DLC1 expression was significantly lower in HCC tissues than in adjacent noncancerous tissues, and DLC-1
expression was found to be negatively correlated with tumor differentiation, TNM stage and lymph node metastasis.
Furthermore, DLC-1 expression was found to inversely correlate with Rho A, ROCK2 and moesin which were all highly
expressed in HCC tissues. Kaplan-Meier analysis showed that significantly longer 5-year survival rate was seen in HCC
patients with higher DLC1 expression, compared to those with lower expression of DLC1. Multivariate Cox proportional
hazard analyses revealed that DLC1 was an independent factor affecting the overall survival probability.
Conclusion: DLC1 could be served as a tumor suppressor gene in the progression especially in the invasion and
metastasis of HCC. DLC1 perhaps played its role by regulating the expression of Rho A, ROCK2 and moesin. Evaluation of
the expression of DLC-1 might be a good prognostic marker for patients with HCC.
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Background
Liver cancer is one of the most common malignancies in
China and the 5-year survival rate of it is very low because
of invasion and metastasis in the early stage [1, 2]. Mecha-
nisms of invasion and metastasis are diverse and not yet
clear-cut in most cases. So the identification of indicators
or markers that may help us to assess tumor behavior of in-
vasion and metastasis are very important for us [3].
Deleted in liver cancer-1 (DLC-1) was first cloned by
using subtractive hybridization method in human hepato-
cellular carcinomas and later it was identified as a breast
cancer metastasis suppressor in microarray comparisons be-
tween breast cancer cell lines [4, 5]. Then, deletion or pro-
moter methylation of DLC-1 has been described in multiple
cancers. DLC-1 is a RhoGAP (GTPase-activating protein)
that inhibits/inactivates Rho-dependent signal transduction
[4, 6]. While Rho is key factors in cell proliferation, polarity,
cytoskeletal remodeling and migration, the aberrant
function of their regulators may lead to cell transformation
[6, 7]. Data showed that DLC-1 mRNA expression was lost
in 95 % of patient with NSCLC tumors tissues and 58 % of
NSCLC cell lines, due at least in part through its function as
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a RhoGAP and thus negatively regulating the expression of
RhoA and related RhoB, RhoC [8]. Nevertheless, a detection
of DLC-1 as a therapeutic indicator or prognostic markers
in liver cancers have litter been elucidated and the role and
mechanism of DLC-1 in liver cancer especially in the inva-
sion and metastasis process remains to be fully eclucidated.
There is considerable and growing evidence for the im-
portance of the ROCK gene in actomyosin contractility,
focal adhesion assembly, cytokinesis and cell proliferation
[9, 10]. ROCK has also been implicated in colorectal [11],
breast [12], gastric [13], and hepatocellular cancer meta-
static growth [14]. One identified mechanism for ROCK
activation in cancer involves the loss of function of the
DLC-1, which encodes a GTPase activating protein
(RhoGAP) for the RhoA and RhoC small GTPases [15].
Moesin, a member of the ERM (moesin, radixin, ezrin)
family of proteins has been reported to be overexpressed in
many kinds of cancers [16, 17]. Leroi et al. [18] sowed that
moesin not ezrin and radixin was up-regulated in glioblast-
oma multiforme in comparison to non-malignant brain tis-
sue samples. In addition, He [19] et al. reported that the
extracellular small GTPase RhoA/ROCK-2 cascade medi-
ated the increased moesin expression and phosphorylation,
however, the relationship between DLC-1 and moesin in
liver cancer has not been evaluated before.
In the current study, the relationship between the expres-
sion of DLC1 and various clinicopathologic parameters and
immunohistochemical markers, such as RhoA, ROCK2 and
Moesin were analyzed. Furthermore, the prognostic signifi-
cance of DLC1 in human HCC was also explored.
Methods
Patient specimens
This study was approved by the Ethics Committee of the
First Affiliated Hospital of Zhengzhou University
(Zhengzhou, Henan, China). Written consents were ob-
tained from all those patients included in this study. A
total of 80 formalin-fixed paraffin-embedded liver cancer
tissues and the corresponding normal tissues were col-
lected from the archive of the First Affiliated Hospital of
Zhengzhou University from 2009 to 2013. None of these
patients received radiotherapy or chemotherapy prior to
surgery. Briefly, the 80 patients consisted of 19 females
and 61 males with ages ranging between 36 and 78 years
old (mean age: 65 years old). According to the newer 2010
TNM classification of malignant tumours, liver cancers
were staged into 54 I-II and 26 III stages. The histological
grade of tumor differentiation was assigned into 61 I–II
stage and 29 III-IV stage. Cancer size was calculated by
measuring the largest dimension of the cancer specimen.
34 cases localized liver cancers without dissemination in
liver and portal vein invasion were viewed as low invasion
groups while other 46 cases with dissemination in liver
and portal vein invasion were viewed as high.
Immunohistochemistry
The immunohistochemistry protocols were described pre-
viously [20]. Primary antibodies against DLC-1, Rho A,
ROCK2 and Moesin were used to detect the corresponding
proteins. Briefly, slides were incubated with 1.5 % H2O2 at
room temperature for 20 min to eliminate the endogenous
peroxidase activity. Then the slides were incubated with a
solution comprising 0.2 % triton-X 100 and 5 % goat serum
at room temperature for 2 h to quench immunoglobulin’s
non-specific binding. After that, the primary antibodies
were added to the slides individually and incubated over-
night at 4 °C. Next day, secondary antibody was applied to
the slides and incubated at room temperature for 2 h. At
last, the immune complexs were visualized by incubating
the sections with DAB. The slides were counterstained with
hematoxylin and mounted. Negative controls were identi-
cally treated with the primary antibodies by PBS.
Immunohistochemistry evaluation
Immunostained sections were evaluated independently by
two pathologists. Immunostaining was evaluated semi-
quantitatively by estimating immunoreactivity extent and
intensity. Staining extent was rated according to the per-
centage of positive cells. Samples with no stained tumor
cells were rated as 0, those with <10 % of stained tumor
cells were rated as 1, those 11–50 % of stained tumor cells
were rated as 2, those with 50–75 % of stained tumor cells
were rated as 3 and those with >75 % of stained tumor cells
were rated as 4. Staining intensity was graded as follows:
negative (0), weak (1), moderate (2) and strong (3). The
overall scores were the product of staining intensity multi-
plied the staining extent. An overall staining score of 0–3
and >3 were regarded as negative (−) and positive (+) pro-
tein expression, respectively.
Statistical analyses
The significant difference of DLC-1, Rho A, ROCK2 and
moesin gene expression between specimen groups was
carried out using the unpaired Student’s t-test. The sur-
vival rates after tumor removal were calculated by the
Kaplan-Meier method, and differences in survival curves
were analyzed by the Log-rank tests. Multivariate survival
analysis was performed on all the significant characteris-
tics measured by univariate survival analysis through the
Cox proportional hazard regression model. Differences
were considered statistically significant when the P-value
was <0.05.
Results
The expression of DLC-1, Rho A, ROCK2 and moesin
proteins in liver cancer tissues
The cellular locations of DLC-1, Rho A, ROCK2 and
moesin proteins were all mainly found in the cytoplasm.
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As shown in Figs. 1a, b; 2a, b; 3a, b and 4a, b, positive
staining rates of DLC-1, Rho A, ROCK2 and moesin in
liver cancer tissue samples were 38.75, 78.75, 75.00 and
86.25 % respectively, which was significantly different
from those in normal mucosa (83.75, 43.75, 40.00 and
66.25 %) (P < 0.001, Table 1).
Clinicopathological significance of the expression of DLC-1,
Rho A, ROCK2 and moesin proteins in liver cancer tissues
Clinicopathological significance of the expression of DLC-
1, Rho A, ROCK2 and moesin proteins in liver cancer tis-
sues are shown in Table 2. We found a negative correlation
between DLC-1 expression and Tumor differentiation
(p < 0.001) and TNM stage (p < 0.001).In addition, the
expression of DLC-1 in low invasion groups was higher
than those in high invasion groups (p < 0.001).
While the expression levels of Rho A, ROCK2 and
moesin were positively correlated with Tumor differenti-
ation, and TNM stage. Furthermore, Rho A, ROCK2
and moesin expression levels were significantly higher in
HCC cancer patients with high invasion ability.
Association between DLC-1 and Rho A, ROCK2, moesin
expression in HCC cancer tissues
Spearman’s rank correlational analysis revealed a significant
negative correlation between the expression levels of DLC-
1 and Rho A, ROCK2, moesin (r = −0.963, −0.669, −0.631).
Survival analysis
HCC patients with low DLC1 expression had lower
disease-free and 5-year survival rates than those with high
DLC1 expression as determined using the Kaplan-Meier
method (Fig. 5). Univariate Cox regression analysis also
identified that clinical variables including gender, tumor
number, maximal tumor size, HBV infection, tumor differ-
entiation, TNM stage and portal vein invasion and dissem-
ination were all positively correlated with overall survival.
Furthermore, to evaluate the potential of DLC1 expression
as an independent prognostic marker for overall survival
of HCC, multivariate Cox regression analyses were per-
formed. While the others failed to demonstrate inde-
pendence, DLC1 expression (HR: 2.234, 95 % CI:
0.937–4.148, p < 0.001), tumor differentiation (HR:
3.769, 95 % CI: 1.925–6.989, P = 0.003), and portal vein
invasion and dissemination (HR: 1.341,95 % CI: 0.843–
2.631, p < 0.001) may play a role in predicting the over-
all survival in HCC (p < 0.05).
Discussion
HCC is one of the most common malignancies worldwide.
Despite advances in the detection and treatment of HCC,
the mortality rate remains high because of early occur-
rence of invasion and metastasis [21]. Hence to improve
early detection of invasion and metastasis and their mo-
lecular characterization in HCC, to develop interventions
Fig. 1 The expression of DLC-1 in HCC tumor and adjacent tissues. a Cytoplasm staining of DLC-1 in HCC tumor tissues (×400). b Cytoplasm
staining of DLC-1 in adjacent normal tissues (×400)
Fig. 2 The expression of RhoA in HCC tumor and adjacent tissues. a Cytoplasm staining of RhoA in HCC tumor tissues (×400). b Cytoplasm staining of
RhoA in adjacent normal tissues (×400)
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that are targeted at blocking or reversing the invasion and
metastasis process are very important for us.
DLC-1 has been known as tumor suppressor gene in
many kinds of cancers including liver, lung, breast, brain,
prostate and colon cancers [22, 23]. And re-expression
of DLC-1 in cancer cells regulates the structure of actin
cytoskeleton and focal adhesions and significantly in-
hibits cell growth, colony formation and invasion cap-
acity, supporting its role as a tumor suppressor [24].
Thus, DLC-1 has the potential to be a key therapeutic
indicator or markers for cancer gene therapy. In the
present study, DLC-1 was found to be lower expressed
in HCC tissues. DLC-1 positive expression was observed
in 31 out of 80 HCC patients. And the lower expression
of DLC-1 was correlated negatively with tumor differen-
tiation and TNM stage. More importantly, the lower ex-
pression of DLC-1 found to be negatively linked with
aggressive clinical behavior. HCC tissues with dissemin-
ation in liver and portal vein invasion showed lower
DLC-1 expression than those in localized tissues without
dissemination in liver and portal vein invasion.
Regarding DLC1 expression, recent reports have shown
a growing interest in its prognostic impact in terms of sur-
vival. In this study, the prognosis of HCC patients with a
low expression of DLC1 was poor, and Cox regression ana-
lysis indicated that low expression level of DLC1 was a
significant prognostic factor for a poor survival rate of
HCC patients. These findings raised the possibility that
lower expression of DLC1 could be a factor of worst
disease-specific survival, independently of any other
variables.
DLC-1 was also named ARHGAP7 because it contains
a RhoGTPase activating protein (RhoGAP) domain and
these domains can convert the active GTP-bound Rho
proteins to the inactive GDP-bound state and negatively
regulate Rho GTPases [25]. RhoA is one of the best-
known members of RhoGAP. ROCKs were originally
isolated as downstream targets of Rho A [26]. RhoA
binding with the C-terminal domain of ROCK, forming
the Rho A/ROCK pathway, and controls a wide variety
of cellular processes dependent on the re-arrangement
of the actin cytoskeleton and changes of cell contractil-
ity. Yet, ROCK does not directly act on cytoskeletal
molecules and ERM (radixin/ezrin/moesin) proteins are
emerged as the candidates that likely linking the activa-
tion of ROCK and the cytoskeleton reorganization [27,
28]. Moesin is one of the most important and it has been
reported that Rho A/ROCK is a typical upstream path-
way for the phosphorylation of moesin [29, 30]. In the
present study, Rho A and ROCK2 expression were found
to negatively correlated with DLC-1 expression. Rho A
and ROCK2 expression were identified in 63 and 60 of
Fig. 3 The expression of ROCK2 in HCC tumor and adjacent tissues. a ytoplasm staining of ROCK2 in HCC tumor tissues (×400). b Cytoplasm staining
of ROCK2 in adjacent normal tissues (×400)
Fig. 4 The expression of moesin in HCC tumor and adjacent tissues. a Cytoplasm staining of moesin in HCC tumor tissues (×400). b Cytoplasm
staining of moesin in adjacent normal tissues (×400)
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the HCC cases. Expression of Rho A and ROCK2 were
all correlated positively tumor differentiation and TNM
stage dissemination in liver and portal vein invasion.
Furthermore, positive expression of Rho A and ROCK2
were also linked with dissemination in liver and portal
vein invasion of HCC tissues. These data indicated that
DLC-1, Rho A and ROCK2 perhaps together played an
important role in the invasion and metastasis of HCC,
and that DLC-1 perhaps played as a tumor suppressor
by inhibiting the activation of Rho A/ROCK2 pathway .
Furthermore, we found that the expression of phosphoryl-
ation of moesin was negatively correlated with the expres-
sion of DLC-1. Positive expression of phosphorylation of
moesin was all correlated positively with tumor differenti-
ation, TNM stage and dissemination in liver and portal
vein invasion. So DLC-1 perhaps exerted its effects in in-
vasion in HCC by regulating the expression of moesin
through the RhoA/ROCK pathway.
Regarding DLC1 expression, recent reports have
shown a growing interest in its prognostic impact in
terms of survival. In this study, the prognosis of HCC
patients with a low expression of DLC1 was poor, and
Cox regression analysis indicated that low expression
level of DLC1 was a significant prognostic factor for a
poor survival rate of HCC patients. These findings raised
the possibility that lower expression of DLC1 could be a
factor of worst disease-specific survival, independently of
any other variables.
Table 1 The expression of DLC-1, RhoA, ROCK2 and moesin in






DLC-1 High 31 67 <0.001
Low 49 13
RhoA High 63 35 <0.001
Low 17 45
ROCK2 High 60 32 <0.001
Low 20 48
moesin High 69 53 <0.001
Low 11 27
Table 2 The relationship between DLC-1, RhoA, ROCK2, moesin and clinicopathological variables in HCC tissues
Clinicopatholog-ical variables DLC1 expression RhoA expression Rock2 expression moesin expression
H L p H L p H L p H L p
Gender
Male 23 38 0.731 48 13 0.98 46 15 0.879 55 8 0.29
Female 8 11 15 4 14 5 15 4
Age (years)
< 45 9 14 0.958 17 6 0.502 17 6 0.887 19 4 0.548
≥ 45 22 35 46 11 43 14 50 7
Tumor number
Singel 20 30 0.767 40 10 0.724 39 11 0.424 43 7 0.933
Multiple 11 19 23 7 21 9 26 4
Maximal tumor size (cm)
< 5 19 30 0.995 38 11 0.742 37 13 0.789 43 6 0.623
≥ 5 12 19 25 6 23 7 26 5
Tumor differentiation
I-II 12 49 <0.001 36 15 0.018 33 18 <0.001 41 10 0.043
III-IV 19 10 27 2 27 2 28 1
HBV infection
No 7 11 0.989 14 4 0.909 13 5 <0.001 15 3 0.683
Yes 24 38 49 13 47 15 54 8
TNM stage
I-II 11 43 <0.001 39 15 0.034 37 17 0.002 44 10 0.074
III 20 6 24 2 23 3 25 1
Portal vein invasion and dissemination
Yes 8 38 <0.001 39 7 <0.001 40 6 0.004 43 3 0.029
No 23 11 14 20 20 14
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Conclusion
DLC-1 appeared to also play as a tumor suppressor gene
in HCC. And DLC-1 might work its way by negatively
regulating the expression of RhoA/ROCK2/ moesin.
DLC-1 itself could be a direct indicator or marker for
the invasion and prognosis of HCC.
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